FibroGen, Inc (FGEN) VP Pat Cotroneo Sells 6,500 Shares of Stock
FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 11th. The shares were sold at an average price of $24.00, for a total value of $156,000.00. Following the completion of the sale, the vice president now owns 138,748 shares of the company’s stock, valued at $3,329,952. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Pat Cotroneo also recently made the following trade(s):
- On Monday, December 12th, Pat Cotroneo sold 2,344 shares of FibroGen stock. The shares were sold at an average price of $22.05, for a total value of $51,685.20.
Shares of FibroGen, Inc (NASDAQ:FGEN) opened at 25.50 on Friday. The firm’s 50-day moving average price is $21.66 and its 200 day moving average price is $19.29. The company’s market capitalization is $1.61 billion. FibroGen, Inc has a 1-year low of $14.38 and a 1-year high of $25.65.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.21. The firm earned $30.10 million during the quarter, compared to analyst estimates of $24.30 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. Equities analysts predict that FibroGen, Inc will post ($0.99) EPS for the current fiscal year.
Several large investors have recently modified their holdings of the company. Hillhouse Capital Management Ltd. bought a new stake in shares of FibroGen during the third quarter valued at about $10,612,000. Vanguard Group Inc. raised its stake in shares of FibroGen by 8.8% in the second quarter. Vanguard Group Inc. now owns 4,220,201 shares of the biopharmaceutical company’s stock valued at $69,254,000 after buying an additional 339,735 shares during the last quarter. Top Ace Asset Management Ltd bought a new stake in shares of FibroGen during the third quarter valued at about $5,121,000. Candriam Luxembourg S.C.A. raised its stake in shares of FibroGen by 77.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 481,000 shares of the biopharmaceutical company’s stock valued at $9,957,000 after buying an additional 210,000 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of FibroGen by 371.5% in the second quarter. American Century Companies Inc. now owns 230,019 shares of the biopharmaceutical company’s stock valued at $3,775,000 after buying an additional 181,235 shares during the last quarter. Institutional investors own 48.23% of the company’s stock.
Several equities research analysts recently issued reports on FGEN shares. Leerink Swann reiterated a “buy” rating and issued a $52.00 price target on shares of FibroGen in a research note on Wednesday, November 9th. Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Friday, November 11th.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.